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Summary
Background The value of quantitative interferon-γ release assay results for predicting progression from Mycobacterium 
tuberculosis infection to active disease is unknown. We aimed to investigate the relation between QuantiFERON-TB 
Gold In-Tube (QFT) conversion interferon-γ values and risk of subsequent active tuberculosis disease and of QFT 
reversion.
Methods We analysed data from a reported vaccine efficacy trial of the tuberculosis vaccine MVA85A in South Africa. 
QFT negative, HIV uninfected young children aged 18–24 weeks were enrolled. We stratified participants by 
quantitative QFT result (interferon-γ <0·35 IU/mL, 0·35–4·00 IU/mL, and >4·00 IU/mL) at the intermediate study 
visit (day 336) and determined risk of progression to active tuberculosis disease over the subsequent 6–24 months. 
No QFT differences were observed between placebo and MVA85A groups at day 336 or end of study; therefore, both 
groups were included in analyses. Study clinicians were not masked to QFT values, but strict case definitions were 
used that excluded QFT results. We used generalised additive models to evaluate the quantitative relation between 
day 336 QFT value and subsequent disease risk, and we compared disease rates between QFT strata using a 
two-sample Poisson test.
Findings Among 2512 young children with QFT tests done at day 336, 172 (7%) were positive; 87 (7%) of 1267 in 
placebo  group and 85 (7%) of 1245 in the MVA85A group (p=1·00). Compared with QFT non-converters (tuberculosis 
disease incidence 0·7 per 100 person-years [95% CI 0·4–1·1]), children with QFT conversion at interferon-γ values 
between 0·35–4·00 IU/mL did not have significantly increased risk of disease (2·5 per 100 person-years 
[95% CI 0·4–9·4]; incidence rate ratio (IRR) 3·7 (95% CI 0·4–15·8; p=0·23). However, QFT conversion at interferon-γ 
values higher than 4·00 IU/mL was associated with substantially increased disease incidence (28·0 per 100 person-years 
[95% CI 14·9–45·7]) compared with non-converters (IRR 42·5 [95% CI 17·2–99·7]; p<0·0001), and compared with 
children with interferon-γ values between 0·35–4·00 IU/mL (IRR 11·4 [95% CI 2·4–107·2]; p=0·00047). Among 
91 QFT converters who were given a repeat test, 53 (58%) reverted from positive to negative. QFT reversion risk was 
inversely associated with interferon-γ value at QFT conversion and was highest with interferon-γ values less than 
4·00 IU/mL (47 [77%] of 61).
Interpretation In young children, tuberculosis disease risk was not significantly increased, and QFT reversion was 
common, following QFT conversion at interferon-γ values up to 10 times the recommended test threshold (0·35 IU/mL). 
By contrast, QFT conversion at very high interferon-γ values (>4·00 IU/mL) warrants intensified diagnostic and 
preventive intervention because of the extremely high risk of tuberculosis disease in these young children.
Funding Aeras, Wellcome Trust, and Oxford-Emergent Tuberculosis Consortium (OETC) were the funders of the 
MVA85A 020 Trial. National Institute of Allergy and Infectious Diseases supported this analysis.
Introduction
Interferon-γ release assays (IGRAs) are diagnostic tests for 
Mycobacterium tuberculosis infection that are widely used in 
high-resource clinical settings to investigate contacts of 
tuberculosis cases and to guide isoniazid preventive therapy 
(IPT).1 Among children, a positive IGRA result could 
improve performance of clinical algorithms for diagnosis 
of pauci-bacillary pulmonary tuberculosis by showing 
previous M tuberculosis exposure and infection. However, 
despite the modest sensitivity and specificity of IGRAs for 
active disease, evidence is conflicting in children.2–8
Young children infected with M tuberculosis are at very 
high risk of progression to tuberculosis disease and, 
compared with adults, are at increased risk of severe 
tuberculosis morbidity and mortality.9 Major interest in the 
use of chemoprophylaxis among high-risk children has 
been shown;10,11 however, randomised trials of untargeted 
IPT among children in high-transmission settings have 
had mixed results. IPT reduces the incidence of disease in 
M tuberculosis-infected or M tuberculosis-exposed children 
by more than 50% and is recommended in national and 
international guidelines.12,13 However, implementation of 
IPT is poor in the resource-limited countries where 
effective tuberculosis prevention is most needed.
One of the key obstacles to targeted tuberculosis 
screening and preventive therapy is differentiating only 
those M tuberculosis-infected individuals at highest risk 
of disease from the majority who will remain healthy. 
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Individuals who test IGRA positive have only two-fold to 
three-fold increased risk for developing tuberculosis 
disease,14–18 and the positive predictive value for disease 
progression among IGRA-positive household contacts, 
or among individuals with IGRA conversion, is less 
than 2%.19,20 Further, because of the absence of natural 
quanti tative breakpoints in the distribution of 
interferon-γ concentrations, the conversion threshold 
value of the QuantiFERON-TB Gold In-Tube test (QFT; 
interferon-γ ≥0·35 IU/mL), one of the most widely used 
IGRAs, is subject to debate.16 Whether higher 
interferon-γ values represent more recent M tuberculosis 
exposure, greater aerosolised inoculum, or sustained 
infection—or simply reflect heterogeneity in human 
immune responses to M tuberculosis—is unclear. 
Importantly, evidence for whether higher QFT 
conversion interferon-γ values are associated with 
increased risk of progression to active disease is 
conflicting,19,21–23 and current management algorithms 
do not distinguish between interferon-γ values above 
the QFT manufacturer’s recommended test threshold 
of 0·35 IU/mL.
We analysed longitudinal data from a tuberculosis 
vaccine efficacy trial, in which no protective effect was 
seen on incidence of M tuberculosis infection or disease 
in a large cohort of Bacille Calmette-Guerin (BCG) 
vaccinated South African young children, all of whom 
were QFT negative at enrolment.24 Infant BCG 
vaccination offers partial protection against pulmonary 
and disseminated tuberculosis disease in children.25 We 
hypothesised that QFT conversions and quantitative 
QFT values predict tuberculosis disease risk among 
young children. We therefore investigated the relation 
between QFT conversion interferon-γ values and risk 
of subsequent active tuberculosis disease and QFT 
reversion.
Methods
Study design and participants
The MVA85A 020 trial was a double-blinded, randomised, 
placebo-controlled clinical trial undertaken in a rural 
region near Cape Town, South Africa, between July 15, 
2009, and Oct 25, 2012. Healthy young children aged 
4–6 months who had received BCG vaccination within 
7 days of birth were enrolled if they were HIV ELISA 
negative and had no known household or other close 
exposure to a tuberculosis patient; QFT testing was done 
and those young children with a positive test were 
excluded.
The trial was approved by the University of Cape 
Town Faculty of Health Sciences Human Research 
Ethics Committee, Oxford University Tropical Research 
Ethics Committee, and the Medicines Control Council 
of South Africa. Parents or legal guardians provided 
written informed consent.
Procedures
Study procedures and results have been described 
previously.24 In brief, young children were randomly 
assigned (1:1) using independently generated sequences 
with block sizes of four to receive one dose of the vaccine 
MVA85A or Candida spp skin test antigen (placebo 
control). QFT testing was done at baseline and was 
repeated at day 336 and at the end of the study, which 
Research in context
Evidence before this study
We searched PubMed for relevant articles published in English 
before July 26, 2016, using the search terms “(Quantiferon OR 
T-Spot.TB OR ‘interferon gamma release assay’) AND (child OR 
children OR pediatric OR infant) AND tuberculosis”. Although 
several studies reported on sensitivity and specificity of 
interferon-γ release assays (IGRAs) for detection of active 
tuberculosis in children, the literature search identified no studies 
reporting prognostic value of IGRA conversions or predictive 
value of quantitative interferon-γ values for tuberculosis among 
young children. Among household contacts of patients with 
tuberculosis, positive IGRAs were associated with increased risk 
of tuberculosis disease, but the positive predictive value was less 
than 2%. Additionally, several studies have noted high rates of 
indeterminate IGRA results among children.
Added value of this study
In this study, we present data from a large prospective cohort of 
young children from a tuberculosis-endemic community who 
were QuantiFERON (QFT)-negative at baseline and followed 
prospectively for QFT conversion, tuberculosis disease, or both. 
We found that very high QFT interferon-γ conversion values 
(>4·00 IU/mL) were associated with substantially increased risk of 
tuberculosis disease compared with non-converters or converters 
with lower QFT interferon-γ values (0·35-4·00 IU/mL). Among 
children who did not convert QFT at 1 year but were subsequently 
diagnosed with disease, all whose QFT was repeated were positive 
at time of diagnosis. Additionally, QFT interferon-γ values above 
the manufacturer’s threshold (0·35 IU/mL) but below 4·00 IU/mL 
were associated with very high rates of reversion.
Implications of all the available evidence
Guidelines from WHO, the US Centers for Disease Control and 
Prevention, and other advisory bodies currently recommend 
tuberculin skin testing over IGRAs for detection of tuberculosis 
infection in young children from high-burden settings, in part 
due to absence of evidence from this age group. These data 
suggest that high QFT interferon-γ conversion values could have 
strong prognostic or diagnostic value for tuberculosis in this 
population. If validated in other study populations, these 
findings justify revision of current international guidelines for 
use of IGRAs for tuberculosis screening in young children.
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ranged from 6 months to 24 months after day 336 and 
was determined by development of tuberculosis disease 
or reaching October, 2012. Young children were actively 
followed every 3 months to identify signs or symptoms of 
disease, or history of exposure to tuberculosis. Children 
with persistent cough, failure to thrive, weight loss, 
positive tuberculin skin test (TST) or QFT conversion, or 
close contact with a patient with tuberculosis were 
admitted for standardised investigation. Investigation 
included QFT and TST (if not already done); chest 
radiography; HIV testing; and testing of two paired, 
consecutive induced sputa and early morning gastric 
lavages by auramine staining and smear microscopy, 
Mycobacteria growth indicator tube liquid culture and 
Xpert MTB/RIF. Children with positive QFT or TST 
results were referred to public clinics for IPT.
In this study, QFT was done according to manufacturer’s 
instructions (Qiagen, Venlo, The Netherlands). Briefly, 
QFT is used to detect in-vitro M tuberculosis-specific 
immune responses by measuring interferon-γ con-
centration in plasma harvested from whole blood 
incubated with M tuberculosis-specific antigens (TB Ag) 
minus interferon-γ detected in unstimulated control (nil). 
The amount of interferon-γ is quantified by ELISA using 
interferon-γ standards between 0 IU/mL and 4 IU/mL 
(outside the USA where standards go up to 8 IU/mL). 
To assess the detectable range of interferon-γ concentration 
beyond the standard curve, blood samples from 42 healthy 
adult volunteers were recruited from the same high 
tuberculosis burden community and were stimulated in 
the TB Ag tube. Undiluted and diluted (1:5, 1:10, and 1:25) 
plasma samples were analysed by QFT interferon-γ ELISA. 
Linearly extrapolated results were compared with each of 
the diluted results to assess reliability of extrapolation 
beyond the highest standard, which was assessed by 
Pearson’s product-moment correlation coefficient.
Outcomes
We defined a positive QFT as TB antigen minus nil 
interferon-γ value greater than or equal to 0·35 IU/mL, as 
per the manufacturer’s instructions. QFT conversion was 
defined as a positive test that followed a negative test, and 
QFT reversion as a negative test that followed a positive 
test. For the original trial, the primary disease endpoint 
(endpoint 1) required either microbiological confirmation 
(defined as at least one positive liquid culture for 
M tuberculosis or Xpert MTB/RIF from any clinical 
specimen) or, in the absence of microbiological con-
firmation, specific chest radiographic and clinical 
findings indicative of tuberculosis disease in addition to 
positive TST or QFT conversion. Study clinicians were 
not masked to QFT results. Because QFT was a 
component of the latter composite definition, we used a 
revised endpoint 1 for this analysis that removed QFT 
conversion from the diagnostic criteria to avoid bias 
towards association with QFT status. Additionally, after 
a tuberculosis disease diagnosis, most children did not 
have QFT repeated, because they had met the main 
study endpoint.
Statistical analysis
Consistent with the primary trial finding that QFT 
conversion and tuberculosis disease incidence did not 
differ by study group,24 we analysed QFT dynamics and 
tuberculosis risk in control and MVA85A vaccine 
participants together. We analysed QFT conversions at 
day 336 and at the end of the study (determined by 
development of tuberculosis disease or October, 2012). 
We compared QFT converters and non-converters at the 
day 336 study visit and analysed subsequent incidence of 
tuberculosis disease through to the end of study. We also 
included tuberculosis cases that were diagnosed within 
60 days of the end of the study, as they probably had 
tuberculosis at the end of the study visit, which in most 
cases prompted the tuberculosis diagnostic process that 
resulted in their diagnosis. We further stratified QFT-
positive results by interferon-γ value at the day 336 study 
visit, first as continuous values, and then using ordinal 
categories based on inspection of model results of disease 
risk, reversion risk, and positive predictive value of 
various thresholds. For our main results, we selected 
thresholds of 0·35 IU/mL (manufacturer’s recommended 
value) and 4·00 IU/mL, because the latter is the maximum 
standard provided in international kits. The relation 
Figure 1: Distribution of QuantiFERON-TB Gold In-Tube (QFT) interferon-γ values at the intermediate study 
visit (day 336)
Bars represent numbers of individuals with QFT values between numbers (eg, 0·01–1·00, 1·01–2·00).
0 5 10 15 20
QFT (IU/mL)
10
0
20N
um
be
r o
f p
ar
tic
ip
an
ts
500
750
1000
1250
1500
Articles
www.thelancet.com/respiratory   Vol 5   April 2017 285
between QFT conversion value, tuberculosis disease 
incidence, and probability of QFT reversion at end of 
study were analysed with logistic regression models and 
generalised additive models with penalised splines. We 
evaluated the effect mediation of sex, age, vaccine 
assignment, and IPT on the relationship between QFT 
value and tuberculosis risk in generalised linear models. 
We calculated exact 95% Poisson CIs and compared 
incidence of tuberculosis disease in groups, expressed in 
incidence rate ratios, using a two-sample Poisson test. 
Data were analysed with R version 3.2.4 (R Foundation 
for Statistical Computing, Vienna, Austria).
Role of the funding source
No additional funding was obtained for this analysis of 
trial data. Aeras was the funder of the MVA85A 020 Trial. 
BSL and JBM are employees of Aeras who participated in 
writing the report. JRA is supported by the National 
Institutes of Health (K01 AI104411). JRA, EN, TJS, and 
MH had complete access to the data. All authors reviewed 
and interpreted analyses and contributed to the writing of 
the report. MH had final responsibility for the decision to 
submit for publication.
Results
Among the 2797 young children enrolled between 
July 15, 2009, and May 4, 2011, in the MVA85A 020 trial at 
median age 20·4 weeks (IQR 19·3–22·0), 2772 (99%) 
young children had a negative QFT at enrolment, 
five (<1%) had no quantitative results available, and 
20 (1%) had an indeterminate result. 1399 young children 
were allocated to MVA85A and 1398 were allocated to 
placebo. Among those 2772 young children with a negative 
QFT at baseline, 2512 (91%) had a QFT done at the day 336 
visit. In this group, 172 (7%) were positive and 13 (1%) 
were indeterminate. Among the 172 QFT converters with 
a positive test at day 336, median QFT conversion 
interferon-γ value was 3·41 IU/mL (IQR 0·82–13·72). 
A bimodal distribution of interferon-γ values was noted, 
with a nadir of about 7·0 IU/mL (figure 1). QFT conversion 
rate did not differ among young children receiving the 
MVA85A vaccine (85 [7%] of 1245 children assigned to 
MVA85A who had QFTs available at day 336) and those 
receiving placebo (87 [7%] of 1267 children assigned to 
placebo who had QFTs at day 336; p=1·00). QFT 
conversion values similarly did not differ for the 
two groups (median 3·46 IU/mL [IQR 0·86–13·19] in the 
MVA85A vaccine group vs median 3·41 IU/mL 
[0·72–13·80] in the placebo group; p=0·83). At the end of 
study visit, 2045 of those children who were QFT negative 
at day 336 had a repeat QFT done and 116 (6%) had 
converted. A non-significant trend towards higher QFT 
conversion among those who were negative at day 336 
was noted in the MVA85A vaccine group compared with 
the placebo group at the end of the study (p=0·090).
Because of the bimodal distribution of interferon-γ 
values, we investigated whether very high QFT conversion 
interferon-γ values, which exceed the maximum value of 
the standard curve and were therefore estimated through 
linear extrapolation, were a reliable estimate of true 
interferon-γ concentrations. In 42 samples from healthy 
adult volunteers with varying interferon-γ values that 
were diluted 5-fold, 10-fold, and 25-fold, we found 
high cor rel ation between extrapolated measurements in 
N Cases Incidence 
(95% CI)
IRR (95% CI) p value
Revised case definition 1
<0·35 IU/mL 2232 16 0·7 (0·4–1·1) Ref Ref
0·35–4·00 IU/mL 79 2 2·5 (0·4–9·4) 3·7 (0·4–15·8) 0·23
>4·00 IU/mL 63 10 28·0 (14·9–45·7) 42·5* (17·2–99·7) <0·0001
Culture or Xpert positive
<0·35 IU/mL 2232 11 0·5 (0·2–0·8) Ref Ref
0·35–4·00 IU/mL 79 2 2·5 (0·4–9·4) 5·4 (0·6–24·8) 0·13
>4·00 IU/mL 63 7 19·6 (8·9–36·8) 43·3† (14·2–122·3) <0·0001
Incidence reported in cases per 100 person-years. IRR=incidence rate ratio. Ref=reference. *IRR of higher than 4·00 vs 
0·35–4·00 for revised case definition 1: 11·4 (95% CI 2·4–107·2), p<0·000047. †IRR of higher than 4·00 vs 0·35–4·00 for 
culture or Xpert positive: 8·0 (95% CI 1·5–78·8); p=0·0094.
Table 1: Incidence of tuberculosis (cases per 100 person-years) according to day 336 QuantiFERON 
interferon-γ value by case definition
Figure 2: Comparison of QuantiFERON interferon-γ values estimated by 
dilutions with QuantiFERON interferon-γ estimates from undiluted values, 
with linear extrapolation above 4 IU/mL
To estimate whether interferon-γ values extrapolated above the assay higher 
standard (4 IU/mL) were reliable, measurements obtained from undiluted 
samples were correlated with those obtained by diluting the same samples 5-fold 
(red marker), 10-fold (blue marker), and 25-fold (green marker). Measurements 
obtained from diluted samples were multiplied by the dilution factor to estimate 
the pre-dilution interferon-γ concentration and correlated with values measured 
in the corresponding undiluted samples. The diagonal dashed line represents 
perfect correlation. The vertical dashed line depicts an undiluted interferon-γ 
value of 12, above which extrapolated results became less reliable.
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un diluted samples and actual measurements in diluted 
samples up to about 12·00 IU/mL (Pearson’s r 0·94–0·97). 
Measurements in undiluted samples underestimated 
interferon-γ concentrations higher than 12·00 IU/mL 
(Pearson’s r 0·66–0·88; figure 2).
Overall, 58 (2%) of 2797 children met diagnostic criteria 
for active tuberculosis disease, including 42 (2%) who 
had microbiologically confirmed tuberculosis. 37 cases 
were diagnosed between day 336 and the end of the 
study, but nine of them were missing day 0 or day 336 
QFT results. An additional 107 children were treated for 
tuberculosis disease, without meeting the study defin-
ition, before day 336 and were excluded from further 
analysis. Among the 172 converters at day 336, 30 were 
diagnosed and treated for tuberculosis before day 336, 
leaving 142 converters available for analysis. Among the 
2232 children with negative QFT at day 336, 16 were 
diagnosed with tuberculosis disease by the end of the 
study (incidence 0·7 per 100 person-years), and 11 of 
them had microbiologically confirmed tuberculosis 
disease (incidence 0·5 per 100 person-years; table 1). Risk 
of tuberculosis disease increased substantially at a 
conversion QFT value of above 4·00 IU/mL (figure 3). 
Among 79 children with a QFT conversion interferon-γ 
value between 0·35 IU/mL and 4·00 IU/mL, two were 
subsequently diagnosed with tuberculosis (incidence 
2·5 per 100 person-years) and both cases were micro-
biologically confirmed (table 1). Among 63 children with 
a QFT conversion interferon-γ value higher than 
4·00 IU/mL, ten were diagnosed with tuberculosis 
(28·0 cases per 100 person-years) and seven were micro-
biologically confirmed (19·6 cases per 100 person-years; 
table 1).
Compared with QFT non-converters, children with 
day 336 QFT conversion interferon-γ values greater than 
4·00 IU/mL had substantially increased incidence of 
active tuberculosis disease by both case definitions 
(incidence rate ratio [IRR] for revised endpoint 1: 
42·5 [95% CI 17·2–99·7]; IRR for microbiologically 
confirmed cases: 43·3 [14·2–122·3]; both p<0·0001). 
Using the threshold of 4·00 IU/mL, the sensitivity and 
specificity for subsequent disease were 36% and 99% and 
the positive and negative predictive values were 16% and 
99%, respectively. The positive and negative predictive 
values using the manufacturer’s cut-off of 0·35 IU/mL 
were 8% and 99%, respectively. Median time to diagnosis 
from the time of QFT testing among QFT non-converters 
was 210 days (IQR 134–373) and among QFT converters 
was 44 days (30–72; p=0·0020), respectively (figure 4). 
Among the 16 individuals with a negative QFT at day 336 
who were subsequently diagnosed with tuberculosis, 
14 had QFT repeated at diagnosis, and all (14 [100%] of 14) 
were positive. We found no effect mediation of vaccine 
assignment (p=0·93), age (p=0·96), sex (p=0·16), 
or receipt of IPT (p=0·79) on the relation between QFT 
values and risk of tuberculosis.
Among the 172 QFT converters at day 336, 91 (53%) 
children had a repeat QFT at the end of the study, and 
53 (58%) reverted from positive to negative QFT. QFT 
reversion rates did not differ by vaccine or placebo 
assignment (29 [56%] of 52 in the MVA85A vaccine group 
vs 24 [62%] of 39 in the control group; p=0·74) or among 
Figure 3: Probability of QuantiFERON-TB Gold In-Tube (QFT) reversion (blue 
line, left axis) between the intermediate and final study visit and 
prospective risk of disease (red line, right axis), as a function of the QFT 
conversion interferon-γ value
The shaded areas reflect 95% CIs from a generalised additive model. Vertical 
dashed line reflects the current recommended cutoff (0·35 IU/mL). 
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those who subsequently received IPT or four-drug 
curative therapy (29 [53%] of 55 who received vs 24 [67%] 
of 36 who did not receive; p=0·27). We analysed risk of 
QFT reversion at the end of the study as a function of the 
QFT conversion interferon-γ value at day 336 (table 2; 
figure 3). At QFT conversion interferon-γ values between 
0·35–4·00 IU/mL, subsequent reversion rates were high 
(47 [77%] of 61). Very high QFT conversion interferon-γ 
values were associated with substantially lower risk of 
QFT reversion (odds ratio 0·07 [95% CI 0·02–0·21] for 
QFT conversion interferon-γ value >4 IU/mL vs ≤4 IU/mL; 
figure 3), although probability of QFT reversion for QFT 
conversion interferon-γ values even above 4 IU/mL 
remained moderately high (six [20%] of 30; table 2).
Discussion
We found high rates of QFT conversion and high 
incidence of tuberculosis disease, using a rigorous 
endpoint definition, in a cohort of young children living 
in a rural community in South Africa. Consistent with 
our previous studies in older populations, we found an 
increased risk of incident tuberculosis disease following 
QFT conversion.18 However, contrary to traditional 
interpretation of the QFT result, we additionally found 
that incidence of tuberculosis disease was significantly 
higher among children with very high QFT conversion 
interferon-γ values (>4·00 IU/mL), with tuberculosis 
disease incidence more than 40-fold that of QFT non-
converters and 11-fold that of QFT converters with 
interferon-γ value between 0·35–4·00 IU/mL. By 
contrast, children with QFT conversion interferon-γ 
values less than 4·00 IU/mL (more than 10 times higher 
than the assay threshold value) had a high risk of QFT 
reversion and did not have significantly increased risk of 
progression to active disease, compared with QFT non-
converters. Together, these results indicate that very high 
QFT conversion interferon-γ values, much higher than 
previously considered clinically useful, are a powerful 
indicator of substantially increased risk for progression 
from M tuberculosis infection to active tuberculosis 
disease in this vulnerable population.
Despite the increased incidence and mortality from 
tuberculosis among children in high-burden countries, few 
large cohort studies have characterised the role of IGRAs to 
predict progression from infection to disease in this 
population. The existing literature consists predominantly 
of cross-sectional studies showing the accuracy of IGRAs in 
the diagnosis of active or latent tuberculosis, frequently in 
comparison with TST. Results have been conflicting at 
times, with some studies showing comparable sensitivity 
and specificity to TST, whereas others found higher or 
lower sensitivity.3,26–32 Rates of indeterminate QFT tests have 
been higher in young children than in adults;26,33–36 although 
in this study, we noted a low rate of indeterminate tests 
(0·4% of all tests).
It is possible that very high QFT conversion interferon-γ 
values among children are a marker of very early, 
incipient disease, or subclinical active disease that was 
present at the time of QFT testing. This hypothesis is 
supported by the relatively short interval between QFT 
testing and diagnosis of tuberculosis disease in very high 
QFT converters in this study. These findings also echo a 
recent study in adolescents that identified increased 
expression of interferon-regulated genes as a predictor of 
subsequent tuberculosis risk.37 The crucial question is 
whether identification of those M tuberculosis-infected 
children at highest risk of having or developing the 
disease offers an opportunity for both early case detection 
of subclinical tuberculosis, and in those children in 
whom aggressive diagnostic measures do not reveal 
tuberculosis, the use of preventive therapy to interrupt 
progression to active disease. Untargeted IPT did not 
prevent tuberculosis among HIV-exposed young children 
in a recent randomised trial;11 whether QFT-targeted 
preventive therapy—with one or more drugs—could 
reduce tuberculosis morbidity and disease in this very 
high-risk population merits further study. Such strategies 
would need to be balanced against the risk of under-
treating undiagnosed active disease, causing selective 
pressure for antibiotic resistance.
Several studies have addressed the question of whether 
QFT interferon-γ values have additional value for 
prediction of incident tuberculosis, and results have been 
conflicting. Diel and colleagues21 found that 16 (84%) of 
19 contacts who subsequently progressed to tuberculosis 
disease had interferon-γ values higher than 3·5 IU/mL at 
initial investigation. In a German study, Geis and 
colleagues22 reported that five (83%) of six contacts with 
disease had interferon-γ values higher than 10 IU/mL, and 
suggested that raising the QFT test threshold could 
improve the positive predictive value and reduce the 
number needed to treat. By contrast, Haldar and 
colleagues23 did not find an association between QFT 
conversion interferon-γ value and progression to 
tuberculosis disease among adult contacts in the UK, and 
Zellweger and colleagues19 found minimal variability in 
risk by interferon-γ value in a cohort of contacts in a large 
European network. Notably, these studies measured 
interferon-γ values in primarily adult tuberculosis contacts 
in low endemicity areas, whereas our study enrolled 
young children in a high transmission area who were 
known to be QFT negative and were then followed 
prospectively for QFT conversion and subsequent disease.
The absence of an inflection point in the distribution of 
interferon-γ values in previous studies has called into 
n Reverted (n [%; 95% CI])
0·35–4·00 IU/mL 61 47 (77%; 64·2–86·5)
>4·00 IU/mL 30 6 (20%; 8·4–39·1)
Total (>0·35) IU/mL 91 53 (58%; 47·4–68·3)
Table 2: Risk of QuantiFERON reversion at end of study, among children 
who converted at the intermediate study visit, according to the day 336 
quantitative QuantiFERON conversion interferon-γ value (IU/mL)
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question the validity of the 0·35 IU/mL test threshold.19 
For the first time, we have shown in young children that 
the distribution of interferon-γ values is clearly bimodal, 
as has similarly been shown previously for the distribution 
of TST in older age groups.19 In the absence of a gold 
standard test, determination of how this distribution 
relates to M tuberculosis infection is impossible, but we 
suggest that based on the nadir of measured QFT 
conversion interferon-γ values at 7·0–8·0 IU/mL, it is 
unlikely that the bimodal distribution differentiates 
M tuberculosis-uninfected children from M tuberculosis-
infected children. We note that this bimodal distribution 
differs from the unimodal distribution of QFT values 
reported in adolescent and adult studies, including one 
from the same laboratory and community, suggesting 
that the naive infant immune response to M tuberculosis 
might differ from that of adults.20
For our main analyses, we selected a threshold of 
4·00 IU/mL based on disease and reversion risks above 
this inflection point (figure 3) and availability of 
interferon-γ standards up to 4·00 IU/mL in the 
international kits. We note that high rates of disease 
(2·5 per 100 person-years) were found even among those 
with QFT values 0·35–4·00 IU/mL, and the optimal 
threshold from a perspective of targeting interventions 
might be lower. Because interferon-γ values greater than 
4·00 IU/mL lie beyond the maximum value within the 
standard curve of the assay, we did several dilution 
experiments using plasma from healthy volunteers and 
noted that observed interferon-γ values estimated 
through linear extrapolation were a reliable estimate of 
true interferon-γ concentrations up to about 12·00 IU/mL, 
suggesting that the observed distribution nadir is not an 
analytical artefact. We infer that the bimodal distribution 
of QFT conversion interferon-γ values might be related 
to other factors such as recent or transient M tuberculosis 
infection, size of inoculum, or bacillary load.
Several recent studies have reported high rates of IGRA 
reversion (>60%) among health-care workers in low-
burden countries.38–41 In a study of adolescents in the 
same high-burden community, we previously reported a 
reversion rate of 23·7% following QFT conversion.20 Very 
few studies of QFT reversion risk among young children 
have been published. Shah and colleagues42 found low 
rates of reversion (15%) among QFT-positive household 
contacts of tuberculosis cases. In this study, we found 
high overall rates of QFT reversion among young 
children (58%) and, as seen in our adolescent study,20 
we found an inverse relation between QFT conversion 
interferon-γ value and reversion risk; however, reversion 
rates remained fairly high (20%) even at very high 
interferon-γ values (>4·00 IU/mL).
The traditional approach to early detection of childhood 
tuberculosis has been the investigation of household 
contacts of adult tuberculosis cases. However, recent 
studies from South Africa have shown that half or more 
of tuberculosis cases in children are not linked to an 
adult case in the household or are diagnosed before the 
adult.43 The use of serial IGRA testing represents a 
potential instrument for early identification of children 
with subclinical or incipient tuberculosis; whether this 
would be cost-effective as a testing strategy, either 
standalone or in conjunction with contact tracing, 
remains to be determined.
The results of this analysis should be interpreted within 
the context of the limitations of the study design and 
available data. First, although we excluded QFT from the 
rigorous case definition for tuberculosis used in this 
analysis, clinicians were not masked to QFT results and it 
is possible that decision to investigate on the basis of a 
positive QFT led to increased diagnosis of tuberculosis 
disease; however, it is unlikely that this would have 
explained the increased disease incidence associated with 
greater quantitative interferon-γ values. Additionally, our 
findings were consistent when using a microbiologically 
confirmed endpoint. To avoid potential for boosting of 
QFT responses, TSTs were not routinely done in this 
study, precluding direct comparison. Children who lived 
in a household with a smear-positive tuberculosis case 
were screened for active tuberculosis; several of such 
children were identified as having active tuberculosis 
before day 336 and therefore not included in the 
prospective analysis. We are unable to assess effect 
mediation between exposures and QFT interferon-γ 
values on tuberculosis risk. Participants with a positive 
QFT who did not have tuberculosis were referred for IPT, 
but IPT did not seem to confound the relation between 
interferon-γ values and risk of disease. We used undiluted 
samples with QFT values extrapolated from the standard 
curve above 4·00 IU/mL in our main analyses, because 
we did not have samples available from this cohort to do 
measurements on diluted samples; our analysis from 
healthy adult controls suggests that this extrapolation 
would be reliable up to 12·00 IU/mL. Several technical 
factors can affect quantitative results of QFT testing, as 
recently outlined by Banaei and colleagues.44 To minimise 
risk of variation, all assays were done according to a trial 
protocol in a single laboratory accredited with the 
South African National Accreditation System (SANAS), 
by well trained technicians with tested competency, under 
a rigorous quality assurance programme, and with 
external monitoring by SANAS and the trial funder, 
Aeras. Finally, we did this study in a community with 
extremely high rates of tuberculosis; whether these 
findings will hold true in lower burden settings should be 
investigated.
Current WHO guidelines recommend that IGRAs not 
be used to replace TSTs in high-burden, low-income, 
and middle-income countries, and several national and 
regional guidelines recommend TSTs over IGRAs 
in young children.12,45 However, many of the same 
guidelines recommend IGRAs preferentially over TSTs 
in BCG-vaccinated individuals, which leaves an evidence 
gap for BCG-vaccinated children. We found that QFT 
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testing in a high-burden, BCG-vaccinated population 
can identify children at highest risk of subclinical 
disease or imminent progression to tuberculosis disease, 
who might benefit from more intensive diagnostic and 
chemotherapeutic interventions. Very high QFT con-
version interferon-γ values (>4·00 IU/mL) in particular 
were associated with lower probability of QFT reversion 
and substantially increased risk of tubercu losis disease. 
By contrast, conversion values in the range of 
0·35–4·00 IU/mL had low predictive value for tubercu-
losis disease and were associated with high rates (77%) 
of reversion. The current recommended QFT threshold 
interferon-γ value of 0·35 IU/mL might therefore be too 
low in this population, and a higher test threshold might 
be indicated for risk-targeted inter vention. Similarly, 
infant QFT conversion values in the range of 
0·35–4·00 IU/mL might warrant repeat testing if pre-
ventive therapy is considered. If validated in other study 
populations, these findings justify revision of current 
international guidelines for use of IGRAs in young 
children.12,45
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